natgillin/translations-raw huggingface dataset:
In patients with renal or cardiac impairment, caution is required since the use of Nimesulide 100mg Tablets/granules may result in deterioration of renal function.
Pri bolnikih z ledvično ali srčno okvaro je potrebna previdnost, ker se lahko zaradi uporabe zdravil, ki vsebujejo nimesulid, poslabša delovanje ledvic.
The risk of undesirable effects may be reduced by using Nimesulide 100mg Tablets/granules for the shortest possible duration (see section 4.2)
Pri uporabi zdravil, ki vsebujejo nimesulid, se lahko nevarnost pojava neželenih učinkov zmanjša tako, da se jih uporablja najkrajši možni čas (glejte poglavje 4.2).
Nimesulide 100mg Tablets/granules should be used for the shortest possible duration, as required by the clinical situation.
Zdravila, ki vsebujejo nimesulid, je treba uporabljati kar najkrajši čas glede na bolnikovo klinično stanje.
Symptoms suggesting a liver condition include loss of appetite, nausea, vomiting, abdominal pain, persistent tiredness or dark urine.
Simptomi, ki kažejo na bolezen jeter, so izguba apetita, navzeja (občutek siljenja na bruhanje), bruhanje, bolečine v trebuhu, nenehna utrujenost ali temen urin.
Concomitant administration with known hepatotoxic drugs, and alcohol abuse must be avoided during treatment with Nimesulide 100mg tablets/granules treatment, since either may increase the risk of hepatic reactions.
Med zdravljenjem z zdravili, ki vsebujejo nimesulid, se morate izogibati sočasni uporabi tega zdravila in znanih hepatotoksičnih zdravil ter zlorabi alkohola, saj se lahko zveča nevarnost pojava jetrnih reakcij.
Children (< 12 years): Nimesulide 100mg Tablets/granules is contraindicated in these patients (see also section 4.3).
Otroci (< 12 let): Uporaba zdravil, ki vsebujejo nimesulid, je pri otrocih kontraindicirana (glejte tudi poglavje 4.3).
Rarely Nimesulide 100mg Tablets/granules has been reported to be associated with serious hepatic reactions, including very rare fatal cases (see also section 4.8).
Poročila o povezanosti zdravil, ki vsebujejo nimesulid, z resnimi jetrnimi reakcijami, tudi zelo redkimi smrtnimi primeri (glejte tudi poglavje 4.8), so redka.
- If you are taking any of the following as they may interact with TRADEMARK: - medicine to thin the blood (anti-coagulants, aspirin or other salicylates) - water tablets (diuretics) used for heart failure or blood pressure - lithium which is used to treat depression and similar conditions - methotrexate - cyclosporin make sure that your doctor or pharmacist knows that you are taking these medicines before taking TRADEMARK.
- Če jemljete katero od spodaj naštetih zdravil, ki lahko medsebojno delujejo z zdravilom TRADEMARK: - zdravila za preprečevanje strjevanja krvi (antikoagulanti, aspirin ali drugi salicilati), - tablete za odvajanje vode (diuretiki), ki se uporabljajo za zdravljenje srčnega popuščanja in visokega krvnega tlaka, - litij, ki se uporablja za zdravljenje depresije in podobnih bolezni, - metotreksat, - ciklosporin.
In women who have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Nimesulide 100mg Tablets/granules should be considered (see section 4.6).
Pri ženskah, ki imajo težave z zanositvijo ali pri katerih potekajo preiskave neplodnosti, je treba - če je to potrebno - zdravljenje z zdravili, ki vsebujejo nimesulid, prekiniti (glejte poglavje 4.6).
- If during treatment with TRADEMARK, you develop fever and/or flu-like symptoms (feeling generally achy, unwell and chills or shivering) you should stop taking the product and inform your doctor.
- Če se med zdravljenjem z zdravilom TRADEMARK pojavi zvišana telesna temperatura in/ali gripi podobni simptomi (splošno slabo počutje, bolečine v mišicah, mrzlica z drgetanjem ali zvišana telesna temperatura), prenehajte z jemanjem zdravila in obvestite zdravnika.
Hepatic impairment: the use of Nimesulide 100mg Tablets/granules is contraindicated in patients with hepatic impairment (see section 5.2).
Jetrna okvara: Uporaba zdravil, ki vsebujejo nimesulid, je kontraindicirana pri bolnikih z jetrno okvaro (glejte poglavje 5.2).
- If you are elderly, your doctor may want to see you at intervals to make sure that TRADEMARK is not causing stomach, kidney, heart or liver problems.
Tako se bo prepričal, da vam zdravilo TRADEMARK ne povzroča težav z želodcem, ledvicami, srcem ali jetri.
Treatment of acute pain (see section 4.2).
4.1 Terapevtske indikacije zdravljenje akutnih bolečin (glejte poglavje 4.2).
Patients who experience symptoms compatible with hepatic injury during treatment with Nimesulide 100mg Tablets/granules (e.g. anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine) or patients who develop abnormal liver function tests should have treatment discontinued.
Pri bolnikih, ki imajo simptome, ki bi lahko kazali na jetrno poškodbo med zdravljenjem z zdravili, ki vsebujejo nimesulid (npr. neješčnost, slabost, bruhanje, trebušne bolečine, utrujenost, temen seč), ali pri tistih, pri katerih se pojavijo nenormalni izvidi preiskav delovanja jeter, je treba zdravljenje prekiniti; nimesulida se jim ne sme več dajati.
TRADEMARK is a non-steroidal anti-inflammatory drug (“NSAID”), with pain-killing and feverlowering properties.
TM je nesteroidno protivnetno zdravilo (“NSAID”), ki blaži bolečine in znižuje telesno temperaturo.
Always take TRADEMARK exactly as your doctor has instructed you.
Pri jemanju zdravila TRADEMARK natančno upoštevajte zdravnikova navodila.
Elderly patients are particularly susceptible to the adverse effects of NSAIDs, including gastrointestinal haemorrhage and perforation, impaired renal, cardiac and hepatic function.
Starostniki so za neželene učinke nesteroidnih antirevmatikov, tudi krvavitve iz prebavil in perforacijo ter ledvično, srčno in jetrno okvaro še posebej občutljivi, zato jih je priporočljivo ustrezno klinično spremljati.
Active gastric or duodenal ulcer, a history of recurrent ulceration or gastrointestinal bleeding, cerebrovascular bleeding or other active bleeding or bleeding disorders.
Cerebrovaskularne krvavitve ali druge aktivne krvavitve ali hemoragijske motnje.
Severe coagulation disorders.
Hude motnje strjevanja krvi.
Severe heart failure
Hudo srčno popuščanje.
Hepatic impairment.
Jetrna okvara.
- Do not take other medicines that are known to affect the liver, e.g. paracetamol or any other pain killers or NSAID treatment - Avoid excess alcohol during treatment with TRADEMARK - If during nimesulide treatment you develop symptoms that suggest a liver condition, you should stop taking nimesulide and inform your doctor immediately.
- Če med zdravljenjem z nimesulidom opazite simptome, ki kažejo na bolezen jeter, prenehajte z jemanjem nimesulida in o tem nemudoma obvestite zdravnika.
Most people recover completely but the illness is usually severe enough to keep people off work for about a month.
Večina ljudi popolnoma okreva, toda bolezen je običajno tako težka, da so bolniki odsotni z dela približno mesec dni.
Vaccination is the best way to protect against these diseases.
Cepljenje je najboljši način zaščite pred tema boleznima.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 10 February 1997
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 10. februar 1997
6 months after the first dose
6 mesecev po prvem odmerku
The safety profile presented below is based on data from approximately 800 subjects.
Povzetek varnostnega profila Prikazan varnostni profil je osnovan na pridobljenih podatkih približno 800 oseb.
• you have a poor immune system due to illness or drug treatment.
• imate oslabljen imunski sistem zaradi bolezni ali zdravljenja z zdravili,
Very rare: System Organ Class
Zelo redki: Organski sistem
Guidelines for boosting are based on the assumption that antibodies are required for protection.
Smernice za obnovitveno cepljenje temeljijo na predpostavki, da so za zaščito nujno potrebna protitelesa.
Inspect the vaccine again: a. If the vaccine appears as a uniform hazy white suspension, it is ready to use - the appearance should not be clear.
Ponovno preglejte cepivo: a. če je cepivo enotna, motno bela suspenzija, je pripravljeno za uporabo - videz ne sme biti bister;
Signs of serious allergic reactions may be rashes that may be itchy or blistering, swelling of the eyes and face, difficulty in breathing or swallowing, a sudden drop in blood pressure and loss of consciousness.
Znako hude alergijske reakcije so lahko izpuščaji, ki so lahko srbeči ali mehurjasti, oteklina okrog oči in obraza, težave pri dihanju in požiranju, nenaden padec krvnega tlaka in izguba zavesti.
However, if you get any of these symptoms you should contact a doctor urgently.
Če se vam pojavi kateri koli od teh simptomov, morate nujno poklicati zdravnika;
• A temporary inflammation of the nerves, causing pain, weakness and paralysis in the extremities and often progressing to the chest and face (Guillain-Barré syndrome)
• začasno vnetje živcev, ki povzročajo bolečino, šibkost in paralizo v okončinah in često napredujejo proti prsnemu košu in obrazu (Guillain-Barré-jev sindrom);
1 PRE-FILLED SYRINGE WITHOUT NEEDLE 10 PRE-FILLED SYRINGES WITHOUT NEEDLE 50 PRE-FILLED SYRINGES WITHOUT NEEDLE 1 PRE-FILLED SYRINGE WITH 1 NEEDLE 10 PRE-FILLED SYRINGES WITH 10 NEEDLES 1 PRE-FILLED SYRINGE WITH 2 NEEDLES 10 PRE-FILLED SYRINGES WITH 20 NEEDLES
1 NAPOLNJENA INJEKCIJSKA BRIZGA BREZ IGLE 10 NAPOLNJENIH INJEKCIJSKIH BRIZG BREZ IGEL 50 NAPOLNJENIH INJEKCIJSKIH BRIZG BREZ IGEL 1 NAPOLNJENA INJEKCIJSKA BRIZGA Z 1 IGLO 10 NAPOLNJENIH INJEKCIJSKIH BRIZG Z 10 IGLAMI 1 NAPOLNJENA INJEKCIJSKA BRIZGA Z 2 IGLAMA 10 NAPOLNJENIH INJEKCIJSKIH BRIZG Z 20 IGLAMI
Such patients may require additional doses of vaccine; nevertheless immunocompromised patients may fail to demonstrate an adequate response.
Ti bolniki bodo morda potrebovali dodatne odmerke cepiva; vendar pa pri imunokompromitiranih bolnikih odziv kljub temu morda ne bo zadosten.
The proportion of subjects reaching anti-HBs ≥ 10 mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix alone.
Delež oseb, ki so dosegle anti-HBs ≥ 10 mi.e./ml, je bil 98,3 % v primeru sočasnega cepljenja in 100 % v primeru cepljenja s cepivom Twinrix samim.
General guidelines for booster vaccination can therefore be drawn from experience with the monovalent vaccines, as follows.
Splošne napotke za obnovitvena cepljenja se zato lahko povzame iz izkušenj z monovalentnimi cepivi, kot sledi.
Pack sizes of 1, 10 and 50 with or without needles.
Velikosti pakiranja: 1, 10 ali 50 z injekcijskimi iglami ali brez njih.
The most commonly reported adverse reactions following Twinrix Paediatric administration are pain and redness occurring in a per dose frequency of 28.5% and 11.5% respectively.
Najbolj pogosto poročani neželeni reakciji po cepljenju s cepivom Twinrix za otroke sta bili bolečina in rdečina s pogostnostjo 28,5 % in 11,5 % na odmerek.
• you have experienced any health problems after previous administration of a vaccine.
• ste po predhodnem cepljenju imeli kakršne koli zdravstvene težave,
In two long term clinical trials, persistence of anti-HAV and anti-HBs antibodies has been demonstrated up to 10 years in children aged 12-15 years and up to 5 years in children aged 1-11
V dveh dolgotrajnih kliničnih preskušanjih so dokazali prisotnost anti-HAV in anti-HBs protiteles še do 10 let pri otrocih, starih od 12 do 15 let, in do 5 let pri otrocih, starih od 1 do 11 let.
• Swelling of the face, mouth or throat (angioneurotic oedema)
• oteklina obraza, ust ali grla (angionevrotični edem);
After a few days the whites of eyes and skin may become yellowish (jaundice).
Po nekaj dneh lahko koža in/ali beločnice postanejo rumenkaste barve
The hepatitis A virus can be passed from person to person in food and drink, or by swimming in water contaminated by sewage.
To bolezen povzroča virus hepatitisa A. Virus hepatitisa A se z osebe na osebo lahko prenaša s hrano in pijačo ali s plavanjem v vodi, onesnaženi s fekalijami.
For some categories of subjects or patients exposed to HBV (e.g. haemodialysis or immunocompromised patients) a precautionary attitude should be considered to ensure a protective antibody level ≥ 10IU/l.
Pri nekaterih kategorijah oseb ali bolnikov, izpostavljenih HBV (npr. bolniki na hemodializi ali imunsko pomanjkljive osebe), je zaradi zagotovitve zaščitnega nivoja protiteles ≥ 10 i.e./l potrebna posebna previdnost.
• Infection around the brain which may give severe headache with stiff neck and sensitivity to light
• okužba okrog možganov, ki lahko povzroči hud glavobol z otrdelim vratom in občutljivostjo na svetlobo (meningitis);
Twinrix Paediatric is a vaccine used in infants, children and adolescents from 1 year up to and including 15 years to prevent two diseases: hepatitis A and hepatitis B. The vaccine works by causing the body to produce its own protection (antibodies) against these diseases.
Twinrix za otroke je cepivo, ki se uporablja pri dojenčkih, otrocih in mladostnikih, starih od enega leta do vključno 15 let, za preprečevanje dveh bolezni: hepatitisa A in hepatitisa B. Cepivo deluje tako, da spodbudi telo k proizvajanju lastne zaščite (protiteles) proti tema boleznima.
In the clinical studies, specific humoral antibodies against hepatitis A were observed in approximately 89% of the subjects one month after the first dose and in 100% one month after the third dose (i.e. month 7).
V kliničnih študijah so specifična humoralna protitelesa proti hepatitisu A ugotovili pri približno 89 % cepljenih oseb en mesec po aplikaciji prvega odmerka cepiva in pri 100 % cepljenih oseb en mesec po aplikaciji tretjega odmerka (to je mesec 7).
Twinrix Paediatric is available in packs of 1, 10 and 50 with or without needles.
Cepivo Twinrix za otroke je na voljo v pakiranjih po 1, 10 in 50 z injekcijskimi iglami ali brez njih.
0.2 milligrams Al3+ - The other ingredients in Twinrix Paediatric are: sodium chloride, water for injections.
0,2 miligrama Al3+ - Pomožne snovi cepiva Twinrix za otroke so: natrijev klorid in voda za injekcije.
AntiHBs geometric mean antibody concentrations were lower on co-administration, but the clinical significance of this observation is not known since the seroprotection rates remain unaffected.
Geometrična sredina koncentracije protiteles anti-HBs je bila med sočasno uporabo manjša, toda klinični pomen tega izsledka ni znan, ker so deleži serološke zaščite ostali neokrnjeni.
• Inflammation of some blood vessels (vasculitis)
• okužba nekaterih krvnih žil (vaskulitis);
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Twinrix Paediatric should be made taking into account the benefit of breast-feeding to the child and the benefit of Twinrix Paediatric therapy to the woman.
Pri odločanju o nadaljevanju/prekinitvi dojenja ali nadaljevanju/prekinitvi cepljenja s cepivom Twinrix za otroke je treba upoštevati tako korist dojenja za otroka kot korist cepljenja s cepivom Twinrix za otroke za mater.
Data on outcomes of a limited number of pregnancies in vaccinated women do not indicate any adverse effects of Twinrix Paediatric on pregnancy or on the health of the fetus/newborn child.
Podatki o izidih nosečnosti, pridobljeni pri manjšem številu cepljenih nosečnic, ne kažejo na možnost škodljivih vplivov cepiva Twinrix za otroke na nosečnost ali zdravje plodu/novorojenca.
• Degenerative disease of the brain (encephalopathy)
• degenerativna bolezen možganov (encefalopatija);
The standard primary course of vaccination with Twinrix Paediatric consists of three doses, the first administered at the elected date, the second one month later and the third six months after the first dose.
Standardno osnovno cepljenje s cepivom Twinrix za otroke sestoji iz treh odmerkov: prvi odmerek apliciramo na izbrani dan cepljenja, drugi odmerek sledi 1 mesec po prvem cepljenju in tretji odmerek 6 mesecev po prvem cepljenju.
Read all of this leaflet carefully before you start/ your child starts receiving this vaccine because it contains important information for you.
Preden boste prejeli/bo vaš otrok prejel cepivo natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
What Twinrix Paediatric is and what it is used for
Kaj je cepivo Twinrix za otroke in za kaj ga uporabljamo
The need for a booster dose of hepatitis B vaccine in healthy individuals who have received a full primary vaccination course has not been established; however some official vaccination programmes currently include a recommendation for a booster dose of hepatitis B vaccine and these should be respected.
Pri zdravih osebah, ki so prejele celotno osnovno shemo cepljenja, ni potrebno obnovitveno cepljenje s cepivom proti hepatitisu B. Kljub temu nekateri uradni programi cepljenja vsebujejo priporočilo za obnovitveno cepljenje s cepivom proti hepatitisu B in ta priporočila je potrebno upoštevati.
0.5 ml of suspension in a pre-filled syringe (type I glass) with a plunger stopper (rubber butyl).
0,5 ml suspenzije v napolnjeni injekcijski brizgi (steklo tipa I) z batnim zamaškom (butilna guma).
It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses as protection in the absence of detectable antibodies may be ensured by immunological memory.
Še vedno ni popolnoma dognano, če imunsko kompetentne osebe, ki so se odzvale na cepljenje s cepivom proti hepatitisu A, potrebujejo obnovitveni odmerek, saj kljub temu, da se protiteles ne zazna, zaščito lahko zagotavlja imunološki spomin.
In situations where a booster dose of hepatitis A and/or hepatitis B is desired, a monovalent or combined vaccine can be given.
V okoliščinah, ko je zaželen obnovitveni odmerek proti hepatitisu A in/ali hepatitisu B, je mogoče uporabiti monovalentno ali kombinirano cepivo.
EU/1/97/029/001 - pack of 1 without needle EU/1/97/029/002 - pack of 10 without needle EU/1/97/029/008 - pack of 50 without needle EU/1/97/029/006 - pack of 1 with 1 needle EU/1/97/029/007 - pack of 10 with 10 needles
EU/1/97/029/001 - pakiranje po 1 brez igle EU/1/97/029/002 - pakiranje po 10 brez igle EU/1/97/029/008 - pakiranje po 50 brez igle EU/1/97/029/006 - pakiranje po 1 z 1 iglo EU/1/97/029/007 - pakiranje po 10 z 10 iglami EU/1/97/029/009 - pakiranje po 1 z 2 iglama EU/1/97/029/010 - pakiranje po 10 z 20 iglami
The safety and immunogenicity of Twinrix Paediatric administered as a booster dose following a three dose primary course have not been evaluated.
Varnost in imunogenost cepiva Twinrix za otroke, uporabljenega kot obnovitveni odmerek po treh odmerkih primarnega cepljenja, nista raziskani.
• Reduction in blood platelets, which increases risk of bleeding or bruising (thrombocytopenia)
• znižanje števila krvnih ploščic (trombocitov), ki zviša tveganje za krvavitev ali pojav modric
What Twinrix Paediatric is and what it is used for What you need to know before you receive Twinrix Paediatric How Twinrix Paediatric is given Possible side effects
Kaj je cepivo Twinrix za otroke in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli cepivo Twinrix za otroke Kako uporabljati cepivo Twinrix za otroke Možni neželeni učinki
• you are allergic to: - the active substances, or any of the ingredients of this medicine (listed in section 6).
- zdravilne učinkovine ali katero koli sestavino tega cepiva (navedeno v poglavju 6).
• Purple or red brown spots visible through the skin (thrombocytopenic purpura)
• rdeče ali rdečerjave lise, ki se vidijo skozi kožo (trombocitopenična purpura);
Influenza like illness*, chills*
redki gripi podobna bolezen*, mrzlica*
• you have a bleeding problem or bruise/ bruises easily.
• imate težave s krvavitvami ali hitrim nastankom modric.
The doctor will give Twinrix Paediatric as an injection into your upper arm muscle or into the thigh muscle of your child.
Zdravnik vam bo dal cepivo Twinrix za otroke v obliki injekcije v mišico nadlakti, vašemu otroku pa v stegensko mišico.
• Generally feeling unwell, tiredness
• splošno slabo počutje, utrujenost,
• Upper respiratory tract infection
• okužba zgornjih dihalnih poti.
Twinrix Paediatric is indicated for use in non immune infants, children and adolescents from 1 year up to and including 15 years who are at risk of both hepatitis A and hepatitis B infection.
Cepivo Twinrix za otroke je indicirano za uporabo pri neimunih dojenčkih, otrocih in mladostnikih, starih od enega leta do vključno 15 let, pri katerih obstaja tveganje za okužbo z virusom hepatitisa A in virusom hepatitisa B.
It is not known if Twinrix Paediatric passes into breast milk, however the vaccine is not expected to cause problems in breast-fed babies.
Ni znano, če cepivo Twinrix za otroke prehaja v materino mleko, vendar pa težav pri dojenih otrocih ne pričakujemo.
• Inflammation of nerves (neuritis)
• vnetje živcev (nevritis);
Twinrix Paediatric is for intramuscular injection, preferably in the deltoid region in adolescents and children or in the anterolateral thigh in infants.
Twinrix za otroke se injicira intramuskularno, najbolje v deltoidni predel pri mladostnikih in otrocih ali v anterolateralni del stegna pri dojenčkih.
Twinrix Paediatric has no or negligible influence on the ability to drive and use machines.
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Twinrix za otroke nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
In haemodialysis patients, patients receiving immunosuppressive treatment or patients with an impaired immune system, the anticipated immune response may not be achieved after the primary immunisation course.
Pri bolnikih na hemodializi, bolnikih, ki prejemajo imunosupresivno terapijo in osebah z okvarjenim imunskim sistemom po osnovnem cepljenju morda ne bo dosežen ustrezen titer protiteles.
However, exceptionally Twinrix Paediatric can be administered subcutaneously to subjects with thrombocytopenia or bleeding disorders since bleeding may occur following an intramuscular administration to these subjects (see section 4.2).
Izjemoma se Twinrix za otroke lahko daje subkutano in sicer bolnikom s trombocitopenijo in bolnikom z motnjami strjevanja krvi, ker lahko pri njih po intramuskularnem injiciranju nastopi krvavitev (glejte poglavje 4.2).
Your doctor will advise on the possible need for extra doses, and future booster dosing.
Vaš zdravnik vam bo svetoval v primeru, da bi potrebovali/bi vaš otrok potreboval dodatne odmerke cepiva in kasnejše obnovitvene odmerke.
The effect of Twinrix Paediatrict on embryo-fetal, peri-natal and post-natal survival and development has been assessed in rats.
Vpliv cepiva Twinrix za otroke na embriofetalno, perinatalno in postnatalno preživetje ter razvoj so ovrednotili pri podganah.
- This vaccine has been prescribed for you/ your child only.
- Cepivo je bilo predpisano vam /vašemu otroku osebno in ga ne smete dajati drugim.
12-15 years, all subjects followed up retained ≥15 mIU/ml anti-HAV antibody and 85% had anti-HBs antibody ≥10 mIU/ml.
1., 6. mesec so se protitelesa anti-HAV vsem spremljanim preiskovancem ohranila na ≥ 15 mi.e./ml in 85 % jih je imelo protitelesa anti-HBs ≥ 10 mi.e./ml.
1 month later
• drugi odmerek: 1 mesec pozneje
• Purple or reddish-purple bumps on the skin (lichen planus), serious skin rashes (erythema multiforme)
• škrlatne ali rdeče-škrlatne izbokline na koži (lichen planus), močan kožni izpuščaj (multiformni eritem), koprivnica;
How to store Twinrix Paediatric Contents of the pack and other information
Shranjevanje cepiva Twinrix za otroke Vsebina pakiranja in dodatne informacije
• Drooping eyelid and sagging muscles on one side of the face (facial palsy)
• povešena veka in mlahave mišice na eni strani obraza (paraliza obraza);
Twinrix Paediatric should under no circumstances be administered intravascularly.
Cepiva Twinrix za otroke se v nobenem primeru ne sme dajati v žilo.
What Twinrix Paediatric looks like and contents of the pack Suspension for injection in pre-filled syringe.
Izgled cepiva Twinrix za otroke in vsebina pakiranja Suspenzija za injiciranje v napolnjeni injekcijski brizgi.
Twinrix Paediatric is not recommended for postexposure prophylaxis (e.g. needle stick injury).
Twinrix za otroke ni priporočljiv za zaščito po predhodni izpostavljenosti (npr. po vbodu z iglo).